What are the guidelines for preventing cisplatin (Platinum-based chemotherapy) induced nephrotoxicity (Impaired renal function)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prevention of Cisplatin-Induced Nephrotoxicity

Adequate hydration before, during, and after cisplatin administration is essential for preventing cisplatin-induced nephrotoxicity, with intravenous fluids required before and after each cycle of cisplatin. 1

Hydration Protocol

Pre-Hydration

  • Administer 1-2 L of isotonic saline prior to cisplatin administration 1
  • Begin hydration several hours before cisplatin infusion

During and Post-Hydration

  • Continue IV fluids for several hours after cisplatin infusion 1
  • Some patients may require continued IV fluids for 5-7 days in outpatient setting to prevent or treat dehydration 1

Alternative Hydration Approaches

  • Short-duration, low-volume hydration regimens have been shown to be effective and safe, even with intermediate to high-dose cisplatin 2
  • Oral hydration after cisplatin may be considered as a safe alternative to IV hydration in appropriate patients, particularly in outpatient settings 3

Electrolyte Management

  • Add 8-16 milliequivalents of magnesium to hydration regimen to prevent hypomagnesemia and provide nephroprotection 1, 2
  • Monitor electrolytes closely, particularly magnesium, calcium, and potassium levels 1
  • Cisplatin administration is associated with hypomagnesemia which may persist long-term 4

Diuresis Management

  • Consider adding mannitol to the hydration regimen for forced diuresis, particularly for high-dose cisplatin and/or patients with preexisting hypertension 5, 2
  • Mannitol has shown nephroprotective effects in multiple studies 2

Dose Considerations

  • Consider lower cisplatin dose (75 mg/m² vs 100 mg/m²) to decrease toxicity 1
  • For intraperitoneal administration, dose reduction to 75 mg/m² may reduce toxicity 1

Monitoring Protocol

Before Each Cycle

  • Monitor renal function before each cycle 1, 6
  • Check BUN, creatinine, serum uric acid, and creatinine clearance 1, 6
  • Renal function must return to normal before another dose of cisplatin can be given 6

During Treatment

  • Watch for early signs of nephrotoxicity 1
  • Monitor for myelosuppression, dehydration, and electrolyte loss 1
  • Monitor peripheral blood counts weekly 6

Special Considerations

Elderly Patients

  • Require closer monitoring due to higher susceptibility to nephrotoxicity 1, 6
  • More likely to have decreased renal function at baseline 6
  • May be more susceptible to myelosuppression and infectious complications 6

Long-Term Effects

  • Long-term nephrotoxicity is frequently asymptomatic but may be associated with up to a 30% reduction in glomerular filtration rate 4
  • Even small reductions in GFR have an adverse impact on cardiovascular disease and all-cause mortality 4
  • Renal function typically decreases in a dose-dependent pattern after cisplatin therapy and then either remains stable or improves during the next 5–10 years 4

Implementation Notes

  • The 6-8 hour infusion with intravenous hydration and mannitol has been used to reduce nephrotoxicity, though renal toxicity can still occur 6
  • Nephrotoxicity has been noted in 28-36% of patients treated with a single dose of 50 mg/m² 6
  • Renal toxicity typically manifests during the second week after a dose 6

References

Guideline

Cisplatin-Induced Nephrotoxicity Prevention

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.